



## Shattuck Labs Announces Participation in Upcoming January Investor Conferences

January 5, 2022

AUSTIN, TX and DURHAM, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: [STTK](#)), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced that company management will participate in two virtual investor conferences in January 2022.

### Presentation Details

Conference: H.C. Wainwright BioConnect 2022 Conference  
Format: Corporate Presentation  
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer  
Date: January 10, 2022  
Time: 7:00 a.m. EST

Conference: 40<sup>th</sup> Annual J.P. Morgan Healthcare Conference  
Format: Corporate Presentation  
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer  
Date: January 13, 2022  
Time: 11:15 a.m. EST

A live webcast of both presentations will be available on the [Events & Presentations](#) section of the Company's website. A replay of the webcasts will be archived for up to 90 days following the presentation date.

### About Shattuck Labs, Inc.

Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company's SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in two Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: [www.ShattuckLabs.com](http://www.ShattuckLabs.com).

### Investor Contact:

Conor Richardson  
Senior Director, Finance & Investor Relations  
Shattuck Labs, Inc.  
[InvestorRelations@shattucklabs.com](mailto:InvestorRelations@shattucklabs.com)

### Media Contact:

Stephanie Ascher  
Managing Director  
Stern Investor Relations, Inc.  
[Stephanie.ascher@sternir.com](mailto:Stephanie.ascher@sternir.com)



Source: Shattuck Labs, Inc.